CDHIC Chengdu Regional Finals Unveil Angel Star and Growth Star Winners

Following the Beijing Division Finals (July 8), Guangzhou Division Finals (July 28), and Hangzhou Division Finals (August 4), the fourth regional final of the China Health and Medical Big Data Industry Innovation Competition (CDHIC)—the Chengdu Division Finals—was successfully held on August 11 in the beautiful "Land of Abundance."

Zhang Lin and Mao Xiaoqin Delivered Addresses, Tang Yin Gave the Keynote Speech, Jointly Looking Forward to the “New Forces” of Medical Innovation in the Chengdu Division

As the organizer of the competition, representatives from CEC Data and CEC Digital Finance welcomed the judges, guests, and participating project representatives on site. They also expressed their gratitude to Starry Sky Capital for its strong support of the Chengdu division finals. The representatives stated that the competition has already been held in Beijing, Guangzhou, and Hangzhou, and they are delighted and full of anticipation for its arrival in the scenic city of Chengdu. The next two regional finals will take place in Wuhan and Beijing (with a special session focusing on Traditional Chinese Medicine and TMT), while the National Grand Final is scheduled to be held at the Beijing Hotel on September 8. Everyone is encouraged to stay tuned.

Vice President of China Electronics Health Industry Fund: Zhang Lin

Ms. Mao Xiaoqin, Partner at Starry Sky Capital, stated: “Starry Sky Capital is deeply honored to co-organize the Chengdu Regional Finals alongside numerous primary and supporting organizations. The path of medical innovation is fraught with challenges, yet the journey offers rewarding vistas. We encourage the projects shortlisted for this regional final to present themselves in peak condition and showcase their greatest strengths. Should performance fall short of expectations, do not be discouraged; after all, there is no problem that Chengdu hotpot cannot resolve.”

Starry Sky Capital Partner: Mao Xiaoqin

Mr. Tang Yin, Vice President of Investment at Medlinker, first expressed Medlinker’s gratitude to the judges and guests for their support of this regional final. He then congratulated the healthcare innovation projects that had stood out from hundreds of applicants to reach the onsite competition, expressing his anticipation for their strong performances. Finally, he provided a detailed introduction to Medlinker from five perspectives: its development history, resources, business model, investment philosophy, and industrial investment layout, sincerely hoping to foster collaborations with many outstanding projects in the future.

Vice President of Medlinker Investment: Tang Yin

Thirty Shortlisted Projects Engage in Fierce On-Site Competition, Showcasing the “New Momentum” of Medical Innovation in the Sichuan-Chongqing Region

The regional finals will officially commence at 9:00 AM and conclude at 5:00 PM. The event will begin with project presentations from the "Rising Star" category, followed by those from the "Angel Star" category. Each "Rising Star" project is allotted 15 minutes for its presentation (including a 10-minute pitch and a 5-minute Q&A session), while each "Angel Star" project is allotted 12 minutes (including an 8-minute pitch and a 4-minute Q&A session). Judges will strictly evaluate each project across six dimensions: technology and service model, business model, industry and market analysis, management team, financial analysis, and on-site defense. The final score for each project will be calculated as the average of the judges' scores after excluding the highest and lowest scores.

The medical innovation projects shortlisted for this regional final span a wide range of fields, encompassing 11 categories in total: medical devices, general health, digital health, biotechnology, healthcare informatics, maternal and child health, consumer healthcare, rehabilitation and nursing, primary care, healthcare finance, and pharmaceuticals. Unlike previous competitions, projects in the digital health and healthcare informatics sectors are no longer the dominant force in the Chengdu division’s finals; instead, the number of projects across all fields shows a trend toward balanced distribution.

Furthermore, the financing rounds of projects shortlisted for the Chengdu division finals were predominantly concentrated in the pre-seed and Series A stages, with a generally high demand for resource empowerment across all projects.

"Rising Star" First Place: Centered on a Team of Senior U.S.-Based Scientists; "Angel Star" First Place: Focused on Infant and Toddler Skin Repair

Chengdu Huahao Zhongtian Biotechnology Co., Ltd. won first place in the “Growth Star” category of the CDHIC Chengdu Regional Finals. Established in 2002, it is the earliest-founded company in this region. Focusing on the pharmaceutical sector, the company has secured Series C financing. As a national high-tech enterprise, it is built around a core team of senior scientists with U.S. experience, leverages its proprietary technology platform, and continuously integrates resources in the biopharmaceutical field. Its primary business focus is the development of novel Class 1 anti-tumor drugs with independent intellectual property rights. The company has already established its presence in gene-engineered microbial fermentation-based anti-tumor drugs and tumor immunotherapy. Its product pipeline includes one chemical drug with “first-in-class” potential and three with “best-in-class” potential. Among these, UTD1 has completed domestic multi-center Phase III clinical trials. As a best-in-class candidate, its Phase III clinical trial results were presented as an oral report at the prestigious American Society of Clinical Oncology (ASCO) annual meeting and published in full in the leading international academic journal The Lancet Oncology, marking a milestone in China’s independent drug research and development.

First Place in Rising Star: Chengdu Huahao Zhongtian Biotechnology Co., Ltd.

Award Presenter: Zhang Lin, Vice President of CEC Health Industry Fund (first from left)

The first-place winner of the "Angel Star" award in the Chengdu Division Finals of the CDHIC competition is Chengdu Huaxi Pharma Biotechnology Co., Ltd. The company was founded by Professor Huang Jing from the West China School of Pharmacy, Sichuan University. Guided by independent research and development, the company is committed to addressing various skin problems through natural approaches. According to the International Study of Asthma and Allergies in Childhood (ISAAC), the global prevalence of infantile eczema ranges from 30% to 60%, while the detection rate in China is as high as 57.3%. Although topical glucocorticoids are the first-line treatment recommended by eczema management guidelines, their use is limited by several factors: a high threshold for application (requiring strict medical supervision and precluding self-medication), cognitive barriers (parents' reluctance to use hormonal treatments for infants), and restrictions on long-term use due to potential side effects. Centering on Osthin™, a natural active ingredient with anti-inflammatory, antipruritic, and reparative properties, Huaxi Pharma has developed the "Infant Osmanthus Multi-Effect Repair Cream." This product is highly safe, free from hormones and antibiotics, effectively alleviates skin itching in affected infants, rapidly repairs skin lesions, and reduces recurrence rates. It not only successfully addresses the health issues faced by many pediatric patients but also significantly alleviates their burden and anxiety, generating substantial social benefits. Currently, the company has established a complete preparation process for extracting this active ingredient and has filed five national invention patent applications and registered four trademarks. In collaboration with Sichuan University under a signed cooperation agreement, the company will continue to optimize its technology and commercialize skincare products for infants and young children, providing better skin repair options for mothers and infants nationwide.

Angel Star First Place: Chengdu Huaxi Fama Biotechnology Co., Ltd.

Award Presenter: Zhou Mi, Managing Partner of Puhua Capital (far left)

CDHIC Chengdu Division Finals – Rising Star Award, Second Place: Beijing iVAX Biotechnology Co., Ltd. Positioned as an R&D-focused biopharmaceutical company, it leverages cutting-edge technologies in immunology to enhance the efficacy and quality of traditional vaccines, designs and develops vaccines and novel drugs, and is committed to becoming a world-class biopharmaceutical company specializing in immunotherapies centered on vaccines and adjuvants.

Runner-up for the Rising Star Award: Beijing iVYBiotech Co., Ltd.

Award Presenter: Li Li, Partner at Starry Sky Capital (far left)

CDHIC Chengdu Division Finals – Angel Star, Second Place: Chengdu Siduoke Medical Technology Co., Ltd. provides compact, non-invasive diagnostic ultrasound devices and services, reducing costs to facilitate adoption in clinical departments and primary healthcare institutions, thereby serving a broader population. These compact, non-invasive ultrasound-based diagnostic devices can be applied across ten specialties, including cardiology, internal medicine, surgery, endocrinology, gastroenterology, gynecology, obstetrics, ophthalmology, urology, and vascular medicine. The company offers collaborative development and joint product initiatives with related medical equipment manufacturers to optimize ultrasound-based products.

Angel Star Runner-up: Chengdu Siduoke Medical Technology Co., Ltd.

Award Presenter: Tang Yin, Vice President of Medlinker Investment (first from left)

Chongqing Xierkang Blood Purification Equipment R&D Co., Ltd., the third-place winner of the “Rising Star” award in the Chengdu division finals of CDHIC, is a high-tech enterprise specializing in the research and development, production, and sales of blood purification devices. The company is dedicated to developing its series of disposable hemoperfusion cartridges with internationally advanced standards, possessing core technologies and independent intellectual property rights.

3rd Place in the Rising Star Award: Chongqing Xierkang Blood Purification Equipment R&D Co., Ltd.

Award Presenter: Bi Yuanfeng, Co-founder of VCBeat (far left)

CDHIC Chengdu Regional Finals – Angel Star Award, Third Place: Sichuan Anyun'er Hospital Management Co., Ltd. The company provides medical services for preconception care, fertility assistance, child healthcare, pediatrics, and pediatric growth and development. It also extends women’s and children’s medical services to home-based healthcare. Adopting a “1+N” chain model (one central outpatient clinic radiating to multiple satellite clinics), the company implements a regional layout. By leveraging its offline outpatient facilities and establishing an online medical service system, it creates an integrated O2O (online-to-offline) service loop.

Third Place, Angel Star: Sichuan Anyuner Hospital Management Co., Ltd.

Award Presenter: Tang Aimin, Healthcare Partner at Panlin Capital (far left)

Mr. Zhou Mi, Managing Partner at Puhua Capital and Co-Chair of the Judging Panel, summarized the project roadshows at the Chengdu Division Finals. He noted that although the overall average quality of the projects was slightly lower than that of the previous three regional finals, several standout projects impressed all the judges with their exceptional strength. He encouraged medical innovation teams in the Sichuan-Chongqing region to continue their efforts with unwavering determination, to develop more high-quality projects, and to leverage this strong momentum to carve out a significant presence in the field of medical innovation.

Zhou Mi, Managing Partner of Puhua Capital and Co-Chair of the Jury Panel

Group Photo of the Judges

To meet the needs of numerous medical innovation enterprises, registration for this year’s China Health and Medical Big Data Industry Innovation Competition will remain open. The finals of the Beijing Division (Traditional Chinese Medicine + TMT Special Session) will be held at Peking University Medical Innovation Valley on August 25. If you wish to register for the competition and compete for limited opportunities to receive support from the national team, please click the link below to access the official competition website or scan the QR code. We look forward to your participation!

Official Website:http://vcbeat.top/cdhic

Scan the QR Code to Register for the Competition